

June 18, 2019

Alberta broadens access to SPINRAZA™ (nusinersen injection)

Dear members of the SMA community,

As part of our promise and commitment to keep the Canadian SMA community apprised of important milestones regarding SPINRAZA™, we are sharing an update on recent developments regarding reimbursement in the province of Alberta.

Effective June 18, 2019, the Alberta Ministry of Health has expanded access to SPINRAZA™. This announcement follows the decision in December 2018 to cover cost of the treatment for those living with Type I SMA.

The following patients in Alberta will now be eligible for reimbursement of SPINRAZA™, in addition to Type I patients:

- patients who are pre-symptomatic with two or three copies of SMN2, or
- have had disease duration of less than six months, two copies of SMN2, and symptom onset after the first week after birth and on or before seven months of age, or
- are under the age of 18 with symptom onset after six months of age, regardless of the ability to walk.
- Other patients who do not meet the expanded funding criteria may be considered in exceptional cases.

Biogen Canada welcomes this news from the Alberta government. It is an important milestone for the SMA community and allows more patients who have been diagnosed with this rare condition to be eligible for reimbursement.

Alberta now joins Quebec, Saskatchewan, Ontario and Non-Insured Health Benefits (NIHB) to provide broad access to SPINRAZA™.

Biogen believes that all SMA patients, including adults, should have broad access and we will continue to work with all jurisdictions until this is achieved in Canada.

Sincerely,

Biogen Canada